Iridex (IRIX) said late Wednesday a peer-reviewed study showed the "sustained safety and efficacy" of MicroPulse Transscleral Laser Therapy in managing both primary and secondary glaucoma over five years.
"These findings suggest MicroPulse TLT can be a viable alternative to invasive incisional glaucoma surgery, particularly in patients with secondary glaucoma and those for whom incisional surgery may be challenging," said Ronald de Crom, who conducted the study with colleagues at the University Eye Clinic Maastricht, Netherlands.
The study assessed 165 pre- and post-cataract eyes treated between 2016 and 2019, with 112 eyes completing the five-year follow-up, the company said. The study was published in Ophthalmology Therapy.
The company's shares surged 20% in recent after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.